Magnesium hydride composition for preventing and treating cancer tumors and preparation process thereof

Abstract

The invention provides a magnesium hydride composition for preventing and treating cancer tumors and a preparation process thereof, and relates to the technical field of magnesium hydride food, and the magnesium hydride composition comprises the following raw materials: magnesium hydride, a cocatalyst, an additive, a carrier material and a lipid hydrophobic material. The co-catalyst, the additive, the carrier material and the lipid hydrophobic material are added, so that the stability and bioavailability of magnesium hydride can be effectively improved; the cocatalyst is beneficial to promoting release of hydrogen at a relatively low temperature, the additive helps magnesium hydride to release hydrogen more easily in vivo, the carrier material increases the stability of magnesium hydride, and the lipid hydrophobic material protects release of magnesium hydride in vivo; the whole process improves the effect of the magnesium hydride as a food additive for preventing and treating esophageal cancer, intestinal cancer, gastric cancer and cardia cancer by optimizing the release and stability of the magnesium hydride.

Description

Technical Field

[0001] The invention relates to the technical field of magnesium hydride food, in particular to a magnesium hydride composition for preventing and treating cancer tumors and a preparation process thereof. Background Art

[0002] Esophageal cancer, intestinal cancer, gastric cancer and cardia cancer are common malignant tumors in the digestive system, each with different causes and risk factors. Types of esophageal cancer: mainly divided into squamous cell carcinoma and adenocarcinoma. Types of intestinal cancer: mainly refers to colon cancer and rectal cancer. Types of gastric cancer: can be divided into adenocarcinoma, lymphoma, etc. Types of cardia cancer: mainly cancer in the cardia of the stomach, usually adenocarcinoma.

[0003] After specific analysis and retrieval, the principle of magnesium hydride in preventing and treating esophageal cancer should be achieved through the release of hydrogen from magnesium hydride, which reduces harmful oxidants in the body and reduces the damage of oxidative stress to cells. First of all, the release of hydrogen from magnesium hydride usually requires high temperature to decompose and release hydrogen. Normally, when magnesium hydride is added to food for consumption, it is difficult for the body to reach the temperature requirement, and magnesium hydride should be difficult to release. Summary of the invention

[0004] 1. Technical issues to be resolved

[0005] In view of the deficiencies in the prior art, the present invention provides a magnesium hydride composition for preventing and treating cancer tumors and a preparation process thereof, which solves the problem that it is difficult to reach the temperature requirement in the body when magnesium hydride is normally added to food for consumption, and magnesium hydride should be difficult to release.

[0006] (II) Technical solution

[0007] To achieve the above purpose, the present invention provides the following technical solution: a magnesium hydride composition for preventing and treating cancer tumors, comprising the following raw materials: magnesium hydride, a co-catalyst, an additive, a carrier material and a lipid hydrophobic material.

[0008] Preferably, the co-catalyst is selected from aluminum or nickel catalysts to help promote the release of hydrogen from magnesium hydride at a lower temperature; the additive is selected from acids or bases to help magnesium hydride release hydrogen more easily in the body.

[0009] Preferably, the carrier material is selected from dietary fiber or protein, which is used to improve the stability and bioavailability of magnesium hydride; the lipid hydrophobic material is selected from vegetable oil or animal fat, which is used to wrap magnesium hydride to protect it from stably releasing hydrogen in the body.

[0010] Preferably, the preparation steps of the magnesium hydride are as follows:

[0011] The magnesium hydride powder is heated to its vaporization temperature under the protection of an inert gas to obtain magnesium vapor;

[0012] cooling the magnesium vapor and collecting the resulting magnesium powder;

[0013] introducing hydrogen gas into a reactor containing magnesium powder;

[0014] At a temperature of 300-400°C and a pressure of 2-5MPa, hydrogen and magnesium powder are fully reacted to generate magnesium hydride.

[0015] Preferably, a process for preparing a magnesium hydride composition for preventing and treating cancer tumors comprises the following steps:

[0016] S1. Mixing magnesium hydride with co-catalyst

[0017] mixing the produced magnesium hydride with a promoter to obtain a mixture, wherein the promoter will help promote hydrogen release from the magnesium hydride at a relatively low temperature;

[0018] S2. Additive treatment

[0019] Adding an acid or base to the mixture helps the magnesium hydride release hydrogen more easily in the body;

[0020] S3. Carrier material mixing

[0021] Dietary fiber or protein is mixed with magnesium hydride and a co-catalyst to form a stable matrix;

[0022] S4. Lipid hydrophobic material encapsulation

[0023] The mixture is mixed with a lipid hydrophobic material to encapsulate the magnesium hydride, which helps to protect the stable release of the magnesium hydride in the body;

[0024] S5. Granulation

[0025] The magnesium hydride-encapsulated mixture is spray-dried or extruded to form stable particles;

[0026] S6. Add to food

[0027] Add magnesium hydride granules to the food at a dose of 0.5 g / kg, ensuring even mixing to obtain a uniform distribution of magnesium hydride;

[0028] S7. Preservation and storage

[0029] Store foods containing magnesium hydride at -20°C to maintain its stability and effectiveness.

[0030] (III) Beneficial effects

[0031] The present invention provides a magnesium hydride composition for preventing and treating cancer tumors and a preparation process thereof. The composition has the following beneficial effects:

[0032] The invention can effectively improve the stability and bioavailability of magnesium hydride by adding a promoter, an additive, a carrier material and a lipid hydrophobic material; the promoter helps to promote the release of hydrogen at a lower temperature, the additive helps magnesium hydride to release hydrogen more easily in the body, the carrier material increases the stability of magnesium hydride, and the lipid hydrophobic material protects the release of magnesium hydride in the body; the overall process optimizes the release and stability of magnesium hydride, thereby improving the effect of magnesium hydride as a food additive for preventing and treating esophageal cancer, intestinal cancer, gastric cancer and cardiac cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is a schematic diagram of the survival status of different groups in Example 3 of the present invention;

[0034] Figure 2 This is a schematic diagram of weight change in Example 3 of the present invention;

[0035] Figure 3 This is a schematic diagram of the esophagus length in Embodiment 3 of the present invention;

[0036] Figure 4 This is a representative image of the pathology of the esophagus in Example 3 of the present invention. DETAILED DESCRIPTION

[0037] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0038] Embodiment 1:

[0039] The embodiment of the present invention provides a magnesium hydride composition for preventing and treating cancer tumors, comprising the following raw materials: magnesium hydride, a co-catalyst, an additive, a carrier material and a lipid hydrophobic material.

[0040] The co-catalyst is selected from catalyst aluminum or nickel, which is used to help promote the release of hydrogen from magnesium hydride at a lower temperature; the additive is selected from acid or base, which is used to help magnesium hydride release hydrogen more easily in the body; the carrier material is selected from dietary fiber or protein, which is used to improve the stability and bioavailability of magnesium hydride; the lipid hydrophobic material is selected from vegetable oil or animal fat, which is used to wrap magnesium hydride to protect it from stably releasing hydrogen in the body.

[0041] The preparation steps of magnesium hydride are as follows:

[0042] The magnesium hydride powder is heated to its vaporization temperature under the protection of an inert gas to obtain magnesium vapor;

[0043] cooling the magnesium vapor and collecting the resulting magnesium powder;

[0044] introducing hydrogen gas into a reactor containing magnesium powder;

[0045] At a temperature of 300-400°C and a pressure of 2-5MPa, hydrogen and magnesium powder are fully reacted to generate magnesium hydride.

[0046] A preparation process of a magnesium hydride composition for preventing and treating cancer tumors comprises the following steps:

[0047] S1. Mixing magnesium hydride with co-catalyst

[0048] mixing the produced magnesium hydride with a promoter to obtain a mixture, wherein the promoter will help promote hydrogen release from the magnesium hydride at a relatively low temperature;

[0049] S2. Additive treatment

[0050] Adding an acid or base to the mixture helps the magnesium hydride release hydrogen more easily in the body;

[0051] S3. Carrier material mixing

[0052] Dietary fiber or protein is mixed with magnesium hydride and a co-catalyst to form a stable matrix;

[0053] S4. Lipid hydrophobic material encapsulation

[0054] The mixture is mixed with a lipid hydrophobic material to encapsulate the magnesium hydride, which helps to protect the stable release of the magnesium hydride in the body;

[0055] S5. Granulation

[0056] The magnesium hydride-encapsulated mixture is spray-dried or extruded to form stable particles;

[0057] S6. Add to food

[0058] Add magnesium hydride granules to the food at a dose of 0.5 g / kg, ensuring even mixing to obtain a uniform distribution of magnesium hydride;

[0059] S7. Preservation and storage

[0060] Store foods containing magnesium hydride at -20°C to maintain its stability and effectiveness.

[0061] By adding co-catalysts, additives, carrier materials and lipid hydrophobic materials, the stability and bioavailability of magnesium hydride can be effectively improved. Co-catalysts help promote the release of hydrogen at lower temperatures, additives help magnesium hydride release hydrogen more easily in the body, carrier materials increase the stability of magnesium hydride, and lipid hydrophobic materials protect the release of magnesium hydride in the body. The overall process improves the effectiveness of magnesium hydride as a food additive for preventing and treating esophageal cancer, intestinal cancer, gastric cancer and cardiac cancer by optimizing the release and stability of magnesium hydride.

[0062] Embodiment 2:

[0063] In combination with Example 1, the present invention provides an experimental scheme of a magnesium hydride composition and a preparation process thereof for preventing and treating cancer tumors:

[0064] a. Animal Model

[0065] Strain: 6-week-old C57BL / 6 female mice (Tang et al., 2004)

[0066] Gender: Female

[0067] Weight: 18-23g.

[0068] b. Consumables

[0069] Chemical inducer: 4-nitroquinoline-N-oxide was selected as the carcinogenic inducer. 4-nitroquinoline-N-oxide was dissolved in propylene glycol to prepare a 6 mg / mL mother solution, which was then divided and frozen at -20°C. When used, it was diluted with water.

[0070] c. Experimental Grouping

[0071] Experimental group (magnesium hydride food group)

[0072] Observation group (model group)

[0073] Control group (blank group).

[0074] d. Model preparation and intervention methods

[0075] The first group (n=33) was the magnesium hydride food group. The 4-nitroquinoline-N-oxide mother solution was diluted with water to 100 μg / mL and provided to the mice for free drinking. Freshly diluted 4-nitroquinoline-N-oxide water was replaced once a week for a total of 16 weeks of drinking 4-nitroquinoline-N-oxide water. After that, ordinary water was replaced and followed up for at least 12 weeks. During this period, the mice were fed with food containing magnesium hydride for 24 weeks.

[0076] The second group (n=50) was the observation group. The mother solution of 4-nitroquinoline-N-oxide was diluted with water to 100 μg / mL and provided to the mice for free drinking. Freshly diluted 4-nitroquinoline-N-oxide water was replaced once a week for a total of 16 weeks of drinking 4-nitroquinoline-N-oxide water. After that, normal water was replaced and regular food was fed during the period for 24 weeks.

[0077] The third group (n=50) was a healthy control group, which used water containing an equal amount of propylene glycol to provide mice with free drinking. Fresh diluted propylene glycol water was replaced once a week for a total of 16 weeks of drinking propylene glycol water. After that, normal water was replaced and regular food was fed during this period for 24 weeks.

[0078] e. General observation

[0079] General conditions, including physiological status, biological behavior, mortality, and weight changes.

[0080] f. Pathological observation

[0081] At specific time points, the tongue, esophagus (placed in a mosquito coil shape), liver, kidney, lung, heart, and brain of the mice were collected, fixed, and embedded in paraffin.

[0082] The specimens fixed with 10% formalin solution were dehydrated with alcohol gradient, transparent with xylene, immersed in wax, embedded in conventional paraffin, and cut into 4μm slices with a slicer. 10 slices of colorectal samples were sliced ​​for each sample. Paraffin slices were dewaxed with xylene, immersed in water with alcohol gradient, rinsed with tap water, stained with hematoxylin for 5 minutes, rinsed with tap water, blued with 1% dilute ammonia for 30 seconds, rinsed, stained with eosin for 5 minutes, rinsed, dehydrated with alcohol gradient, transparent with xylene, and sealed with neutral gum. The slides were digitized with a digital scanner to observe histological changes.

[0083] g. Statistical analysis

[0084] SPSS 21.0 statistical software was used to perform statistical processing on clinical data. Chi-square (X2) test was used for count data. The measurement data were expressed as mean ± standard deviation (X±s). The variance homogeneity test was performed first. If the data were in accordance with the normal distribution, the independent sample t test was performed. If the data were not in accordance with the normal distribution, the rank sum test was performed and then the independent sample t ord was performed. P < 0.05 was considered to be significantly different.

[0085] Embodiment three:

[0086] like Figure 1-4 As shown, in combination with Example 1 and Example 2, the present invention provides a magnesium hydride composition for preventing and treating cancer tumors and the experimental results and analysis of the preparation process thereof:

[0087] a. Death

[0088] During the 6-month period, there was no death in the blank group. There were 7 deaths in the model group and 3 deaths in the experimental group. Figure 1 .

[0089] b. Weight changes

[0090] Reference Figure 2 There were significant differences in body weight changes among the three groups.

[0091] c. Length of esophagus

[0092] Reference Figure 3 There were significant differences in esophageal length among the three groups (P<0.001).

[0093] d. Pathological analysis

[0094] After the mice were treated, esophageal HE sections were prepared. The results showed that the effect of the experimental group was significantly better than that of the control group. Figure 4 . (Attached Figure 4 On the left is the full-length esophageal pathological section of each group, in the middle is the esophageal epithelial thickness identified by AI, and on the right is the statistical difference between the two groups).

[0095] In summary, the experimental conclusion is: Animal experiments in vivo have shown that hydrogen-rich water can reduce the incidence of esophageal cancer.

[0096] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A magnesium hydride composition for preventing and treating cancer tumors, characterized in that: The invention comprises the following raw materials: magnesium hydride, a co-catalyst, an additive, a carrier material and a lipid hydrophobic material.

2. A magnesium hydride composition for preventing and treating cancer tumors according to claim 1, characterized in that: The co-catalyst is selected from aluminum or nickel catalysts, and is used to help promote the release of hydrogen from magnesium hydride at a lower temperature; the additive is selected from acid or base, and is used to help magnesium hydride release hydrogen more easily in the body.

3. A magnesium hydride composition for preventing and treating cancer tumors according to claim 1, characterized in that: The carrier material is selected from dietary fiber or protein, and is used to improve the stability and bioavailability of magnesium hydride; the lipid hydrophobic material is selected from vegetable oil or animal fat, and is used to wrap magnesium hydride to protect it from stably releasing hydrogen in the body.

4. A magnesium hydride composition for preventing and treating cancer tumors according to claim 1, characterized in that: The preparation steps of the magnesium hydride are as follows: The magnesium hydride powder is heated to its vaporization temperature under the protection of an inert gas to obtain magnesium vapor; cooling the magnesium vapor and collecting the resulting magnesium powder; introducing hydrogen gas into a reactor containing magnesium powder; At a temperature of 300-400°C and a pressure of 2-5MPa, hydrogen and magnesium powder are fully reacted to generate magnesium hydride.

5. A process for preparing a magnesium hydride composition for preventing and treating cancer tumors, characterized in that: The following steps are involved: S1. Mixing magnesium hydride with co-catalyst mixing the produced magnesium hydride with a promoter to obtain a mixture, wherein the promoter will help promote hydrogen release from the magnesium hydride at a relatively low temperature; S2. Additive treatment Adding an acid or base to the mixture helps the magnesium hydride release hydrogen more easily in the body; S3. Carrier material mixing Dietary fiber or protein is mixed with magnesium hydride and a co-catalyst to form a stable matrix; S4. Lipid hydrophobic material encapsulation The mixture is mixed with a lipid hydrophobic material to encapsulate the magnesium hydride, which helps to protect the stable release of the magnesium hydride in the body; S5. Granulation The magnesium hydride-encapsulated mixture is spray-dried or extruded to form stable particles; S6. Add to food Add magnesium hydride granules to the food at a dose of 0.5 g / kg, ensuring even mixing to obtain a uniform distribution of magnesium hydride; S7. Preservation and storage Store foods containing magnesium hydride at -20°C to maintain its stability and effectiveness.

Images